Roche (SWX: RO, ROG;OTCQX: RHHBY) and Evotec (FSE: EVT; NASDAQ:EVTC) announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds USD 300 million. Evotec will be responsible for conducting Phase II studies for EVT 101, a compound originally discovered by Roche and developed from discovery stages through clinical studies by Evotec. pharmaceutical product
A team of 20 UK Trade & Investment (UKT&I) commercial staff from across the world – including China, USA, Brazil, India, Malaysia and Thailand – have visited Yorkshire to gain a deeper understanding of the British healthcare sector. Helping to further support UK businesses internationally, the week-long visit offered a valuable insight into the UK healthcare technology sector, highlighting the expertise that is taking place across Yorkshire and throughout the rest of the country. pharmaceutical product
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. pharmaceutical product
The Special Committee of the Board of Directors of Genentech, Inc. (NYSE:DNA) today urged Genentech shareholders to take no action at this time with respect to Roche’s revised tender offer to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $93 in cash per share. Currently, Roche owns approximately 55.8% of the outstanding shares of Genentech. pharmaceutical product
Pharmaceutical chemistry and Drug: Specialty pharmaceuticals to .To investigate this trend, AVOS Life Sciences have analysed the performance of the top 14 pharmaceutical companies with respect to the overall group’s average share of portfolio sales derived from specialty products. .
Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining .Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen .
Dragon Pharmaceutical Inc.: Leading Multinational Pharmaceutical Client Increases Clavulanic Acid Order by 250% for 2009 (CCNMatthews Finance) VANCOUVER, BRITISH COLUMBIA– – Dragon Pharmaceutical Inc. , a leading international pharmaceutical company, today announced that it has received a 14-ton follow-on supply order for its Clavulanic Acid products from a fast-growing multinational pharmaceutical company whose products are distributed in the United States and in over 40 countries in Europe, the Middle East and North Africa.
Pharmaceutical supply chain | Products and services | Cardinal HealthThrough our Pharmaceutical Distribution business, Cardinal Health consolidates product orders from hundreds of manufacturers into pharmacy-specific deliveries for retail .
